P/E ratio for Sangamo Therapeutics (SGMO)

P/E ratio history for Sangamo Therapeutics from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Gilead Sciences GILD	18.6	-1,740.46%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	> 1000	-447,286.71%	🇺🇸 USA
Amgen AMGN	25.5	-2,346.13%	🇺🇸 USA
Biogen BIIB	16.6	-1,562.85%	🇺🇸 USA
Dow DOW	-14.3	1,158.56%	🇺🇸 USA
Johnson & Johnson JNJ	19.4	-1,805.74%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	19.5	-1,820.27%	🇺🇸 USA
Merck MRK	13.2	-1,258.61%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.